Quote Request
Target Discovery & Validation for Pancreatic Cancer
Pancreatic cancer (PC) has an insidious occurrence and inferior prognosis, and it is difficult to obtain specimens at different stages and to observe the tumorigenesis and progression. Alfa Cytology is an integrated research, development, and manufacturing organization providing scientific services, ranging from early discovery and development to preclinical research. Here, we provide target discovery and validation services for pancreatic cancer therapy development.
Introduction to Pancreatic Cancer Targets
As understanding of the biology and molecular characteristics of pancreatic cancer continues to expand, drug development that targets a variety of specific tumor signaling pathways has been recognized as a promising approach to improving options for pancreatic cancer. More and more small-molecule inhibitors of pancreatic cancer have been discovered and developed. There are a large number of small molecules under investigation. As potential pancreatic cancer therapy agents, they have shown encouraging antitumor activity and promising safety and tolerability in early studies.
- Inhibitors of protein phosphatase 2A (LB-1008)
- Inhibitors of focal adhesion kinase (C49)
- Dual inhibitor of focal adhesion kinase and pyruvate kinase 2 (PF-5622717)
Pancreatic cancer is a common gastrointestinal tumor with unmet needs. The disease is characterized by multi-gene, multi-step complex evolution from onset to spread. To move beyond the current dire situation of the lack of pancreatic cancer therapy options, identifying the best protocols and new treatment options is a challenge that must be faced.
Fig. 1 Personalized pancreatic cancer targeted therapies. (Leroux, C.; & Konstantinidou, G., 2021)
Our Services
The selection of research targets is an important part of drug discovery. Our goal is to help researchers discover new, effective pancreatic cancer therapy targets. We have an in-depth understanding of pancreatic cancer cell and receptor biology, its inherent molecular heterogeneity, and in particular, the complex molecular pathology of pancreatic cancer improved by genomic analysis.
| Target Discovery | Target Validation |
|---|---|
|
|
Target Discovery & Validation Strategies
With a range of platforms and expertise in pancreatic cancer research and therapeutic areas, we deliver many new therapy target-related services to our customers.
Cancer genome sequencing
Whole-genome sequencing (WGS) using next-generation sequencing (NGS) provides base-pair level analysis of mutations specific to cancer tissue.
- Single nucleotide locus variants (SNV)
- Copy number variations
- Insertions/deletions (indel)
- Structural variants
In vitro and in vivo target validation
Alfa Cytology provides many popular pancreatic cancer models which are useful tools for drug target validation.
Imaging platform and ELISA screening
Based on the imaging and ELISA screening platform of Alfa Cytology, we help our customers analyze how the therapy interacts with a target at the subcellular level, optimizing identification strategies.
Genome-wide RNA interference (RNAi)
RNAi provided by Alfa Cytology is used to understand how cancer genes interact in dynamic networks, helping to prioritize certain target loci that may be particularly important in pancreatic cancer.
Our Services Support These Targets
Why Choose Us?
Customized solution
Highly-experienced expert team
Variety of preclinical models
Quick turnaround time
Worldwide service
Alfa Cytology is committed to assisting our customers with pancreatic cancer therapy development research and providing customers with target discovery and validation services for pancreatic cancer therapy. If you are interested in our services, please contact us for more details. You can get in touch with our staff directly and receive professional, reliable, and fast feedback.
References
- Leroux, C.; & Konstantinidou, G. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Cancers 2021, 13, 799. https://doi.org/10.3390/cancers13040799
